View clinical trials related to Bariatric Surgery.
Filter by:Comparative study to explore the effect of opioid free anesthesia technology in perioperative analgesia management, clarify the effect of naborphine instead of opioids on perioperative analgesia management in morbid obesity patients with moderate and severe OSA, reduce related adverse events, and explore the latest clinical anesthetic drugs.
This study aimed to analyze spatio-temporal characteristics of gait, physical activity level and changes in quality of life in patients by measuring conditions before bariatric surgery and third-month after the surgery.
decipher the role of microbiota in glycemic response change after bariatric surgery
This study was conducted as a randomized controlled trial to determine the effects of e-mobile education and counselling service on self-care agency, body image, and quality of life in patients undergoing bariatric surgery. The sample of the study was determined using power analysis after making preliminary tests with the patients who met the sample selection criteria in Isparta City Hospital Obesity Center, and consisted of 51 (26 experiment, 25 control) patients. The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months. The data of the study were collected using the Personal Information Form, Self-Care Agency, Body Image, and Moorehead Ardelt Quality of Life II (MA-II) Scales prepared in accordance with the literature. In addition to descriptive statistics, Chi-Square, Independent Samples t-test, Repeated Measures, Mann-Whitney U and Friedman tests were used to evaluate the data. A statistically significant difference was found in the mean scores of Self-Care Strength, Body Image, MA-II and BMI of the patients in the experimental and control groups according to the processes (p>0.05). There was no statistically significant difference between the groups in terms of preoperative, 1st, 2nd, and 3rd month Self-Care Power, Body Image and MA-II scale mean scores (p>0.05). There was a statistically significant difference between the groups in favour of the experimental group in terms of the 1st, 2nd, and 3rd month BMI averages (p<0.05).
Obesity can be a major driver for the development of chronic kidney disease (CKD), which is a leading cause of death and significant loss in quality of life. A growing body of evidence has shown bariatric (metabolic) surgery as a novel approach to reduce the progression of CKD and reduce morbidity with sustained weight loss. This pilot trial will inform the design and execution of a large RCT that could determine the efficacy of bariatric surgery in the treatment of patients with CKD in the context of obesity. Ultimately, the results have the potential to influence guidelines that may deem bariatric surgery as a viable treatment option for CKD and reduce the morbidity from this chronic condition and inform clinical practice.
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM). This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM. The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults with diabetes undergoing bariatric surgery. Subjects will be randomized to receive of intranasal oxytocin or placebo (8 units 3 times daily) for 8 weeks prior surgery. Study visits include screening to determine eligibility, CGM will be connected before and after oxytocin administration, and 1 year post surgery. blood tests including oral glucose tolerance test will be done and fat samples will be taken during surgery. The investigator's hypothesis is that oxytocin administration prior bariatric surgery can induce diabetes remission in patients with diabetes
Postoperative nausea and vomiting (PONV) is unpleasant and increases health care costs. Despite modern techniques and prophylaxis, PONV rates remain high after laparoscopic bariatric surgery. We aim to reduce PONV after laparoscopic bariatric surgery using aprepitant with a similar scheme used for emetogenic chemotherapy.
The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.